{"disease":{"id":"cutaneous-melanoma-stage-iv","name":"cutaneous melanoma stage iv"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01274338","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1673,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02506153","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1301,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03677739","title":"Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1160,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":false},{"nct_id":"NCT01989572","title":"Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":815,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03819296","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02339571","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04593277","title":"Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03663647","title":"Advanced Melanoma in Russian Experience","phase":"","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"MelanomaPRO, Russia","has_results":false},{"nct_id":"NCT03698019","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07148245","title":"Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT02196181","title":"Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02224781","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":267,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01134614","title":"Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02419495","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":221,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04067960","title":"Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01950390","title":"Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04990726","title":"Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04511013","title":"A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT07155317","title":"Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03033576","title":"Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05102773","title":"The Effect of the Microbiome on Immune Checkpoint Inhibitor Response in Melanoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01708941","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01258855","title":"Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01989585","title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03025256","title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00937937","title":"Dinaciclib in Treating Patients With Stage IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01590069","title":"Aerosolized Aldesleukin in Treating Patients With Lung Metastases","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01738139","title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01480154","title":"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06391099","title":"Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02129075","title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02298959","title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02595866","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05039801","title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06319196","title":"Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT02519322","title":"Neoadjuvant and Adjuvant Checkpoint Blockade","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02910700","title":"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06265285","title":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04645680","title":"Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01644591","title":"Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03384836","title":"Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":47,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT02965716","title":"Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05907512","title":"Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}